1
ALL1
Pierre FabreYear
1
ALL1
2023DEALS // DEV.
1
ALL1
DealsCountry
1
ALL1
FRANCE1
ALL1
Terran BiosciencesTherapeutic Area
1
ALL1
Psychiatry/PsychologyStudy Phase
1
ALL1
Phase IIDeal Type
1
ALL1
Licensing AgreementProduct Type
1
ALL1
Small moleculeDosage Form
0
ALLLead Product
1
ALL1
IdazoxanTarget
0
ALLLead Product(s) : Idazoxan
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase II
Sponsor : Terran Biosciences
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : Under the agreement, Terran obtains exclusive global development and commercialization rights for idazoxan hydrochloride, a selective alpha 2 receptor antagonist and a late-stage clinical therapeutic for the treatment of schizophrenia.
Product Name : Undisclosed
Product Type : Small molecule
Upfront Cash : Undisclosed
June 02, 2023
Lead Product(s) : Idazoxan
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II
Sponsor : Terran Biosciences
Deal Size : Undisclosed
Deal Type : Licensing Agreement